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Objectives. We determined the effect of adjunctive inhibition of
the extrinsic coagulation pathway by factor VIIa–tissue factor
complex inhibitors, DEGR VIIa and tissue factor pathway inhib-
itor (TFPI), and the selective factor Xa inhibitor, tick anticoagu-
lant peptide (TAP), after thrombolytic therapy with tissue-type
plasminogen activator (t-PA) in a canine model of electrically
induced coronary thrombosis.
Background. Ongoing thrombin generation is considered an
important component of the heightened thrombin activity associ-
ated with thrombolytic therapy and may be responsible for
reperfusion failure and reocclusion.
Methods. Forty-two dogs with electrically induced coronary
thrombus undergoing thrombolysis with t-PA (1 mg/kg over
20 min) were randomly assigned to one of the following adjunctive
regimens: TAP (30 g/kg body weight per min for 90 min, n 10);
TFPI (100 to 150 g/kg per min for 90 min, n  10); DEGR VIIa
(1- to 2-mg/kg bolus, n 10) and saline control (n 12). The dogs
were observed for 120 min after thrombolysis for reocclusion.
Results. All three active study agents accelerated the time to
reperfusion by an average of 12 min (all p < 0.05). Duration of
reﬂow was greatest with TAP (117  8 min, p < 0.05 compared
with saline control), whereas DEGR VIIa and TFPI did not
prolong the duration of reﬂow. Reocclusion rates were similar
among control, DEGR VIIa and TFPI groups (70%, 78% and 67%,
respectively). Tick anticoagulant peptide reduced the occurrence
of reocclusion (0%, p < 0.05 compared with saline control).
Conclusions. In this experimental model, during systematic
blockade of various extrinsic coagulation pathway proteins, we
demonstrated that whereas acceleration of thrombolysis occurs
with factor VIIa–tissue factor complex inhibition, optimal en-
hancement of thrombolysis was achieved through speciﬁc factor
Xa blockade.
(J Am Coll Cardiol 1996;28:1858–65)
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Despite substantial advances in the application of intravenous
thrombolytic agents and the adjunctive use of antiplatelet and
antithrombotic therapies, current thrombolytic intervention
still does not achieve the goal of early, complete and sustained
reperfusion in a majority of patients (1). Ongoing thrombin
activity during thrombolysis is considered a major impediment
to “optimal” reperfusion. Yet we and other investigators have
found that agents such as heparin and hirudin, which inhibit
thrombin activity but allow ongoing thrombin formation, may
not enhance thrombolysis as effectively as agents that speciﬁ-
cally inhibit thrombin generation (2–4).
The extrinsic pathway is considered primarily responsible
for intravascular thrombus formation in vivo (5,6). The expo-
sure of subendothelial tissue factor (TF) during plaque ﬁssur-
ing and rupture results in the formation of activated factor
VII–TF complexes and cascading activation of coagulation
proteins, leading to generation of thrombin and ﬁbrin forma-
tion. Recombinant DNA technology has recently made agents
available that selectively inhibit key enzymes in the extrinsic
coagulation pathway. Tick anticoagulant peptide (TAP) is a 60
amino acid protein derived from the soft tick, and is a potent
and highly selective inhibitor of factor Xa (7). Recombinant
tissue factor pathway inhibitor (TFPI) is a multivalent protein-
ase inhibitor whose complex actions result in inhibition of the
factor VIIa–TF complex (8,9). Inhibition of the factor
VIIa–TF complex can also be achieved by DEGR VIIa
(ZymoGenetics)—an inactivated form of factor VIIa that still
binds to TF but cannot catalyze factor X activation.
We hypothesized that adjunctive inhibition of the extrinsic
coagulation pathway would prevent ongoing thrombin gener-
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ation and enhance the efﬁciency of tissue-type plasminogen
activator (t-PA)-induced thrombolysis. Adjunctive inhibition
of the factor VIIa–TF complex by TFPI and DEGR VIIa was
compared with selective factor Xa inhibition by TAP after
thrombolytic therapy with t-PA in a canine model of electri-
cally induced coronary thrombosis. The length of time required
to achieve thrombolysis, extent of thrombolysis, incidence of
acute rethrombosis and effects on markers of coagulation were
evaluated.
Methods
Coronary artery thrombus formation. All procedures per-
formed conformed to the guidelines of the American Physio-
logical Society and were approved by the Animal Research
Committee of the Cleveland Clinic Foundation. The method-
ology used to induce an occlusive coronary thrombus has been
described in detail elsewhere (10,11). Brieﬂy, a 2-cm length of
the left circumﬂex artery was isolated in 42 anesthetized
mongrel dogs of either sex, weighing 21 2.0 kg. An ultrasonic
Doppler ﬂow probe (Crystal Biotech) was placed on the artery
for coronary blood ﬂow measurement. Thrombosis was in-
duced using the electrolytic injury technique (12). The endo-
thelium was manually injured; a silver-coated copper electrode
wire with a 26-gauge needle tip was inserted into the isolated
artery segment; and a vascular occluder, placed around the
vessel distal to the ﬂow probe and the electrode, was adjusted
to induce80% diameter stenosis. Thrombosis was induced by
the delivery of 100 A of anodal current to the tip of the
electrode, and the occluder was gradually removed after
thrombus formation. Continuous mean aortic blood pressure
and electrocardiographic monitoring was performed. Hemody-
namic measurements were continuously recorded on a mul-
tichannel recorder (MFE). Catheters were inserted in both
femoral veins and advanced into the inferior vena cava for
infusion of the various therapeutic regimens and collection of
blood samples.
Administration and dose selection of study agents. A
period of 30 min was allowed to elapse after the formation of
a fully occlusive coronary thrombus to conﬁrm the stability of
thrombus. The dogs then received t-PA (1 mg/kg body weight
over 20 min) together with one of the following adjunctive
treatments: 1) a control group of 12 dogs was given normal
saline at a rate of 0.6 ml/min for 90 min; 2) 10 dogs received
TAP at 30 g/kg per min for 90 min; 3) recombinant TFPI was
given at the initial dose of 100 g/kg per min in 6 dogs and
150 g/kg per min to 3 dogs, all for 90 min; and 4) DEGR VIIa
was given to 7 dogs in a bolus of 1 mg/kg, and to 3 dogs in a
bolus of 2 mg/kg.
The dose of TAP was based on previous experiments in our
laboratory, which identiﬁed the threshold dose that suppressed
increases in markers of thrombin activity, ﬁbrinopeptide A and
thrombin–antithrombin complexes during thrombolysis in dogs
(4). We previously demonstrated effective inhibition of factor
VIIa by DEGR VIIa in a cell-surface chromogenic assay using
rat smooth muscle cells (13). Activity of DEGR VIIa against
canine thromboplastin has also been demonstrated in in vitro
clotting assays, although higher concentrations of DEGR VIIa
were required with rabbit and baboon thromboplastin (unpub-
lished data). The eventual dose of 1.0 mg/kg of DEGR VIIa
was chosen based on the results of a dose-response study in the
baboon, which found this dose to be in gross excess for the
prevention of thrombus formation (14). The initial dose of
TFPI was based on earlier studies demonstrating that doses
between 50 and 100 g/kg per min were associated with plasma
levels of 2 to 5 g/ml and inhibition of reocclusion after
thrombolysis in a canine femoral artery model (15,16).
Dose regimens for each of the active study agents were
reviewed at an interim analysis of the study results, which was
prespeciﬁed in the study design protocol. If the incidence of
reocclusion was 50% after the ﬁrst six preparations, the dose
of the study agent was increased. At the interim analysis,
reocclusion had occurred in four of six dogs in the DEGR VIIa
group and in three of six dogs in the TFPI group. The doses of
TFPI and DEGR VIIa were therefore increased (by 50% for
TFPI and by 100% for DEGR VIIa) for the remaining four
dogs in the TFPI group and in three of the remaining four dogs
in the DEGR VIIa group (the fourth dog did not receive the
higher dose because of limited amounts of the study drug).
There were no instances of reocclusion in the ﬁrst six dogs in
the TAP-treated group, and the dose of TAP was not changed.
Thrombolysis was deﬁned as restoration of coronary blood
ﬂow to at least 30% of the baseline value, occurring at any time
after the onset of t-PA infusion. Reocclusion was deﬁned as
occurrence of zero blood ﬂow after successful initial throm-
bolysis. Dogs were observed for a 2-h period from the occur-
rence of thrombolysis for evidence of coronary reocclusion. In
those dogs with intermittent restoration of coronary blood ﬂow
due to cyclic ﬂow variations, the total duration of reperfusion
was calculated as the length of time blood ﬂow was greater
than zero during the 2-h period after the onset of reperfusion.
Study agents. Recombinant t-PA was supplied as a powder
in 50-mg vials by Genentech. DEGR VIIa was provided by
ZymoGenetics, Inc. and was prepared as described previously
(13). Recombinant TFPI was supplied by Monsanto Co. The
preparation of this agent has also been previously described
(16,17). Tick anticoagulant peptide was supplied by Merck &
Co. and was prepared as previously described (4,18).
Abbreviations and Acronyms
aPTT  activated partial thromboplastin time
BT  bleeding time
DEGR  active-site inactivated factor VIIa
FPA  ﬁbrinopeptide A
PT  prothrombin time
TAP  tick anticoagulant peptide
TAT  thrombin-antithrombin complex
TF  tissue factor
TFPI  tissue factor pathway inhibitor
t-PA  tissue-type plasminogen activator
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Coagulation activity studies and template bleeding time.
Anticoagulated whole blood samples for prothrombin time
(PT), activated partial thromboplastin time (aPTT), thrombin–
antithrombin complex (TAT) and ﬁbrinopeptide A (FPA)
levels were collected at baseline (before thrombus formation),
at the end of the t-PA infusion, at the end of the adjunctive
therapy administration and at the end of the experiment (i.e.,
1 h after the end of adjunctive treatment). Fibrinopeptide A
concentrations were measured in plasma samples after ﬁbrin-
ogen was removed by Bentonite treatment by a modiﬁed
procedure based on competitive enzyme-linked immunosor-
bent assay (ELISA) as previously described (4,19). Thrombin-
antithrombin complex levels were determined using a commer-
cially available ELISA kit (Asserachrom A.T.M., American
Bioproduct Co.). Species cross-reactivity for both FPA and
TAT was tested, with canine samples demonstrating 37%
cross-reactivity for FPA and 100% cross-reactivity for TAT
with human plasma samples (4,19). For gum bleeding time
(BT) determination, an inner lip incision was made with a fully
automated incision-making instrument (Surgicutt, Interna-
tional Technidyne Corporation). Blood ﬂow was blotted every
30 s after the incision using blotting paper until bleeding
stopped.
Measurement of TFPI and DEGR VIIa plasma levels.
Immunoassay of TFPI. Plasma TFPI was measured by particle
concentration ﬂuorescence immunoassay as previously de-
scribed (20). Standards and plasma samples were diluted in a
buffer containing phosphate buffered saline, 10 mg/ml bovine
serum albumin and 0.05% Tween 20, pH 7.2. A 40-l aliquot
was incubated at room temperature for 1 h with 15 l of a
0.25% suspension of monoclonal anti-TFPI–IgG-bound car-
boxylpolystyrene particles. Anti-human TFPI antibodies la-
beled with ﬂuorescein isothiocyanate were added (30 l) and
incubated for 30 min. The concentration of TFPI was mea-
sured by standard and sample comparative ﬂuorescence con-
centration on a Pandex PCFIA analyzer (21).
Analysis of DEGR VIIa antigen. The plasma concentration
of DEGRVIIa–treated dogs were determined using ELISA, as
previously described (13). The assay uses a monoclonal-
polyclonal sandwich format with an anti-human factor VIIa
monoclonal antibody and a rabbit anti-human polyclonal an-
tibody (both obtained from Walt Kisel, University of New
Mexico). The concentration of DEGR VIIa in the dog plasma
was determined by comparing the absorbance in the test
sample to the DEGR VIIa standard curve.
Data analysis. Measures of thrombolytic efﬁcacy for the
four study agents were compared by analysis of variance
(ANOVA). Special attention was paid to the multiple compar-
isons nature of this analysis. Dunnett’s test was used to
compare each of the three active agents’ responses with the
saline control. For pairwise comparisons among active treat-
ment groups, a Bonferroni type correction was used to main-
tain the overall signiﬁcance level at alpha 0.05. For categorical
variables, pairwise comparisons were made using the Fisher
exact test and Bonferroni type corrections. Three comparisons
were performed in each of the contrasts, resulting in a critical
value of p  0.017, which was considered signiﬁcant.
A repeated measures type of analysis was performed to
determine treatment effects on coagulation variables and gum
BT. Each dog’s response curve over time was ﬁtted into a
summary slope measure for each of the variables measured.
Treatment effect was determined by comparing the summary
slope measures with ANOVA techniques. Because of the
nonlinear nature of the response curves, summary slope mea-
sures included coefﬁcients for both linear and quadratic effects.
Multivariate ANOVA (Hotelling’s T2 test) was used to com-
pare treatment effects. Because of the multiple (three) com-
parisons performed, a Bonferroni type correction was applied
to maintain an overall signiﬁcant of alpha 0.05, giving a critical
value of p  0.017, considered signiﬁcant. All data were
analyzed using the SAS software package.
Results
Effects of adjunctive antithrombotic agents on thromboly-
sis and acute reocclusion. Baseline left circumﬂex artery ﬂow
velocities were similar among the four treatment arms. The
mean (SD) time taken for occlusive thrombus to form was
73.0  31.0 min (range 23 to 136). In the saline control group,
the mean time to reperfusion was 32.4  12.7 min. All three
active treatment groups demonstrated accelerated thromboly-
sis compared with the control group (all p  0.05, Table 1),
with similar times to onset of reperfusion in each of the three
active treatments.
Table 1. Measures of Efﬁciency of Thrombolysis With Study Agents
Saline Control
(n  12)
DEGR VIIa
(n  10)
TFPI
(n  10)
TAP
(n  10)
Reperfusion achieved 9 (75%) 9 (90%) 9 (90%) 10 (100%)
Time to reﬂow (min) 32  13 20  7* 21  6* 18  10*
Reﬂow duration (min) 62  45 70  48 91  35 117  8*
Cyclic ﬂow variations (in dogs
with initial reperfusion)
8 (89%) 7 (78%) 5 (56%) 0*
Reocclusion (in dogs with initial
reperfusion)
8 (89%) 7 (78%) 6 (67%) 0*
*p  0.05 versus saline control group. Data presented are mean value  SD or number (%) of dogs. TAP  tick
anticoagulant peptide; TFPI  tissue factor pathway inhibitor.
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There were signiﬁcant differences in the duration of reper-
fusion and incidence of cyclic ﬂow variations and reocclusion
among the three active treatment arms. The total duration of
ﬂow was greatest in the TAP-treated group. Compared with
saline control, adjunctive TAP therapy resulted in an almost
twofold increase in mean duration of ﬂow (117  8 min vs.
62  45 min, p  0.05, Table 1). In contrast, DEGR VIIa and
TFPI therapy did not prolong the total duration of reperfusion
compared with saline control. The duration of reﬂow at 100%
or greater than the baseline ﬂow rate—a marker of the
integrity and efﬁciency of thrombolysis—was also greatest in
TAP-treated dogs (117 8 min with TAP vs. 47 43 min with
DEGR VIIa and 71  50 min with TFPI, p  0.0001). Both
TAP (p  0.0001) and TFPI treatment (p  0.004) resulted in
longer periods of ﬂow at or greater than 100% of the baseline
ﬂow rate, compared with DEGR VIIa treatment, which was
not signiﬁcantly different from saline control.
The incidence of cyclic ﬂow variations in the four treatment
groups is shown in Table 1. Although DEGR VIIa and TFPI
did not reduce the occurrence of cyclic ﬂow variations com-
pared with saline control, there were no instances of cyclic ﬂow
variations in TAP-treated dogs (p  0.001 compared individ-
ually with TFPI, DEGR VIIa and control). Rates of reocclu-
sion of the treated vessel are also shown in Table 1. There were
no reocclusions in the TAP-treated group, and this reocclusion
rate was signiﬁcantly lower than with TFPI (p  0.009) or
DEGR VIIa (p  0.002). Reocclusion rates of these last two
treatments were not signiﬁcantly different from saline control.
The doses of DEGR VIIa and TFPI were both increased
after six experiments in each group, as prespeciﬁed in the study
protocol, because observed reocclusion rates were50% (four
of six dogs with DEGR VIIa and three of six dogs with TFPI).
The dose of DEGR VIIa was increased from a bolus of 1.0 to
2.0 mg/kg, and the dose of TFPI was increased from a 90-min
infusion at 100 to 150 g/kg per min. There was no improve-
ment in the efﬁciency of thrombolysis noted with the increased
doses of either agent (Fig. 1). The mean time to reperfusion
was unchanged for both agents compared with the lower doses,
while reocclusion occurred in all dogs receiving the higher
doses of both DEGR VIIa and TFPI.
Effects on hemostatic variables. The responses of PT and
aPTT to the four study agents are shown in Figures 2 and 3,
respectively. Tissue factor pathway inhibitor prolonged PT up
to 7.4-fold above baseline, which was unexpected. In contrast,
TAP and DEGR VIIa produced mild prolongation of PT and
were not signiﬁcantly different from saline control. No differ-
ences in aPTT response were noted among the four treatment
arms. Gum BT was signiﬁcantly prolonged by TAP (4.7 times
above baseline, p  0.004 compared with control) and TFPI
(3.5 times above baseline, p  0.003 compared with control).
DEGR VIIa did not prolong gum BT to a greater extent than
the saline control did (Fig. 4).
There were signiﬁcant increases in FPA and TAT levels in
the saline control group, particularly at the end of the t-PA
infusion period, indicating heightened thrombin activity with
thrombolysis. Fibrinopeptide A formation over time was sup-
pressed with TFPI (p  0.023) and TAP (p  0.01) compared
with control, whereas DEGR VIIa did not suppress FPA levels
(Fig. 5). All three active agents suppressed TAT formation
compared with control (p  0.002 for all), although the
effect was more marked in the TFPI- and TAP-treated
groups (Fig. 6).
Figure 1. Schematic showing the coronary patency
for individual dogs. Time 0 indicates commencement
of t-PA infusion. In the TFPI group, six dogs re-
ceived the agent at the dose of 100 g/kg per min,
whereas the remaining four (*) received 150 g/kg
per min. In the DEGR VIIa group, seven dogs were
given a bolus of 1 mg/kg, and the remaining three (*)
received a 2-mg/kg bolus. All 10 dogs in the TAP
group received the agent at a dose of 30 g/kg per
min (see text for details). Dog 7 in the TAP group
died suddenly from ventricular ﬁbrillation. Postmor-
tem analysis of the circumﬂex artery demonstrated
continued patency, without any macroscopic throm-
bus. CFVs  cyclic ﬂow variations.
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Hemodynamic responses. No changes in heart rate during
sinus rhythm were noted in any of the four treatment groups
during the course of the experimental protocol. Baseline
systemic blood pressure was similar among all four groups.
There were no differences in blood pressure response with
treatment with DEGR VIIa, TFPI or TAP compared with
saline control.
TFPI and DEGR VIIa plasma levels. The mean TFPI
plasma level concentrations, measured in six dogs before
receiving TFPI, were undetectable. After administration of the
dose of 100 g/kg per min for 90 min, TFPI levels were 8.2 
5.5 g/ml at 20 min, 15.6  7.4 g/ml at 90 min and 1.1 
1.3 g/ml at 150 min.
Using an assay that does not detect canine factor VII, after
a bolus injection of 1 mg (n  7) or 2 mg (n  3) of DEGR
VIIa, the levels of DEGR VIIa were 6.9  5.3 g/ml and
11.7  06 g/ml (at 1 and 2 mg, respectively) at 20 min, 4.1 
2.0 g/ml and 6.3  1.8 g/ml at 90 min and 3.0  1.3 g/ml
and 5.8  0.7 g/ml at 150 min.
Discussion
This study demonstrated that the efﬁciency of thrombolysis
can be improved with adjunctive antithrombotic therapy tar-
geted at the extrinsic coagulation pathway. The agents DEGR
VIIa and TFPI both inhibit the factor VIIa–TF complex,
whereas TAP selectively inhibits factor Xa. The efﬁcacy of
Figure 2. Graph illustrating PT values during administration of study
agents. TFPI markedly prolonged PT up to 7.4 times above baseline. In
contrast, TAP and DEGR VIIa did not change PT signiﬁcantly,
compared with the saline control.
Figure 3. Graph illustrating aPTT values during administration of
study agents. None of the agents signiﬁcantly prolonged aPTT com-
pared with the saline control.
Figure 4. Plot showing the effect of study agents on gum bleeding time.
DEGR VIIa did not prolong gum bleeding time compared with the
saline control. In contrast, gum bleeding time was prolonged 4.7 times
above baseline by TAP and 3.5 times above baseline by TFPI.
Figure 5. Plot illustrating FPA values during administration of study
agents. The FPA levels increased in the saline control group after
thrombolytic therapy. In contrast, FPA formation was suppressed with
both TFPI and TAP, whereas DEGR VIIa did not suppress ﬁbrino-
peptide A.
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inhibition of the TF–factor VIIa–factor Xa pathway in accel-
erating thrombolysis (by an average of 12 min for all three
active study agents) is consistent with the already established
role of TF in initiating intravascular thrombosis (5,6). Yet,
neither DEGR VIIa nor TFPI successfully prevented acute
reocclusion, even at the higher doses tested.
It is possible that the lack of efﬁcacy demonstrated with
these two agents relates to the continuing catalytic effect of
small amounts of factor VIIa–TF complex that escape block-
ade. The ampliﬁcation process inherent in the early portion of
the coagulation pathway facilitates formation of signiﬁcant
quantities of thrombin, even if only small amounts of factor
VIIa–TF are present. Thus, virtually total inhibition of factor
VIIa–TF complex may be necessary if this strategy is to be an
effective adjunct to thrombolysis. Furthermore, factor Xa that
is already formed has been found to contribute to rethrombosis
(22,23), and is not controlled by factor VIIa–TF blockade.
In contrast, inhibition of factor Xa effectively prevented
acute rethrombosis and was associated with the greatest sup-
pression of markers of thrombin activity. Factor Xa is an
integral component of both intrinsic and extrinsic coagulation
pathways and is involved in several feedback loops that amplify
the generation of thrombin, independent of factor VIIa–TF
(24,25). The presence of factor Xa within the lysing clot has
also been shown to have considerable procoagulant activity,
not reliant on the presence of thrombin (23,26). Furthermore,
plasmin generated by thrombolytic therapy acts paradoxically
to stimulate thrombin formation (27) and can activate the
contact system (28) and factor V (29). These procoagulant
effects of plasmin are theoretically blocked by TAP, but not by
agents that only inhibit factor VIIa–TF complex.
We observed that TAP administration abolished cyclic ﬂow
variations during reperfusion, whereas TFPI and DEGR VIIa
treatments did not. All three study agents were tested in
animals with a complex thrombus composed of platelets and
ﬁbrin (11). Cyclical build-up and embolization of platelet
thrombi have been suggested as mechanisms behind cyclic ﬂow
variations (30). It is noteworthy that inhibition of thrombin
generation by TAP markedly reduces both ﬁbrin and platelet
deposition to the arterial surface after thrombolysis (31). In the
present study, the morphology of the residual thrombus after
treatment with either TFPI or DEGR VIIa was not assessed.
Thus, further investigations are needed to determine whether
the failure of inhibition of factor VIIa–TF complex to remove
residual platelets is responsible for the cyclic ﬂow variations
and reocclusion in these experimental groups.
We observed varying effects on hemostatic variables among
the three active agents. The modest elevation of PT associated
with the factor Xa inhibitor, TAP, has been observed in a
number of previous studies (3,32–34). Although DEGR VIIa
resulted in similarly modest PT prolongation, TFPI markedly
prolonged PT up to 7.4 times the baseline value. This ﬁnding is
at variance with previous studies of TFPI in canine models
(15,16). The explanation for these discrepant ﬁndings is un-
clear and will need to be addressed in future experiments with
this agent. Prolongation of gum BT with TAP and TFPI,
observed in this study, has been reported previously (16,33,35),
although BTs in our study were substantially longer.
We measured markers of thrombin activity and correlated
them with the study’s in vivo ﬁndings. Fibrinopeptide A and
TAT principally reﬂect thrombin activity and are only indirect
measures of thrombin generation. The observation that these
markers could be suppressed by agents that were otherwise
ineffective in vivo (DEGR VIIa and TFPI) points to a rela-
tively low sensitivity of FPA and TAT in discriminating signif-
icant alterations in thrombin generation. Unfortunately, direct
measurement of thrombin generation by prothrombin frag-
ment 12 cannot be determined in the dog with currently
available assays.
Comparison with previous studies. A number of studies
have previously demonstrated the beneﬁt of TAP as an adjunct
to thrombolysis (2–4,33–35). We and other investigators have
compared TAP with the direct thrombin inhibitor, hirudin, in
the canine thrombolytic model (2–4). Although hirudin was
beneﬁcial as an adjunct to thrombolysis in experimental and
clinical studies (36–39), comparisons of TAP and hirudin have
clearly shown that the potential utility of direct thrombin
inhibition is signiﬁcantly limited by its lack of suppression of
ongoing thrombin generation (2–4).
Accordingly, our study went further to explore the effect of
“higher tier” blockade of the coagulation pathway on the
efﬁciency of thrombolysis. Haskel et al. (15) previously dem-
onstrated that TFPI (previously known as lipoprotein-
associated coagulation inhibitor) prevented reocclusion in a
canine femoral artery model of platelet-rich thrombus. The
same workers subsequently evaluated TFPI in a canine coro-
nary artery model, similar to the one used in our study. In
contrast to our results, they found that TFPI did not accelerate
thrombolysis, but did improve reocclusion rates compared with
control (16). Although these ﬁndings are difﬁcult to reconcile
with our own, differences in methodology and preparation of
the thrombus may be responsible, and comparisons with other
Figure 6. Plot illustrating TAT complex values during administration
of study agents. The TAT complex increased in the saline control
group after thrombolytic therapy. All three active agents suppressed
TAT complex formation compared with saline control.
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extrinsic pathway inhibitors were not performed. In contrast to
TFPI, DEGR VIIa has not been previously tested as an
adjunct to thrombolysis. However, a monoclonal antibody
directed against TF has been shown to inhibit thrombus
formation (40,41) and improve thrombolysis (42) in a rabbit
model. To our knowledge, our study is the ﬁrst to compare the
effects of three separate and distinct inhibitors of the extrinsic
pathway on thrombolysis.
As the search for the most effective treatment for acute
coronary thrombosis evolves, it appears that the efﬁcacy of
adjunctive agents that speciﬁcally inhibit thrombin activity,
such as heparin and hirudin, may still be limited by permitting
ongoing thrombin formation. This study has demonstrated that
inhibition of thrombin generation by blockade of the extrinsic
coagulation pathway, at one of several points, is effective at
accelerating thrombolysis. However, selective inhibition of the
strategically important coagulation protein, factor Xa, rather
than blockade of factor VIIa–TF complex, provided the great-
est protection against acute reocclusion. It is envisaged that on
the basis of this and other studies, a reﬁned adjunctive
approach to thrombolytic therapy can be formulated that
combines effective suppression of thrombin formation and
inhibition of thrombin and platelet activity to achieve the
ultimate goal of “optimal” reperfusion.
Study limitations. First, our study used an animal model of
acute coronary thrombosis, and its results may not extend to
coronary reocclusion occurring more than a few hours after
thrombolysis. Second, dose-response studies with the various
study agents were not performed during this experiment.
However, preliminary studies were performed to determine
the minimal dose of TAP required to produce suppression of
markers of thrombin activity in the canine model (4). The dose
of TAP chosen was signiﬁcantly lower than in previous studies
(2,3). Yet, this dose proved effective and did not cause
excessive disturbance of hemostasis. The dose of TFPI was
based on earlier dose-response studies, and the mean TFPI
plasma concentrations obtained in our study are comparable
with those previously published (15,16). We acknowledge that
an insufﬁcient dose of DEGR VIIa cannot be excluded as an
explanation for the observed lack of efﬁcacy and minimal
effects on coagulation variables. However, the circulating levels
of DEGR VIIa measured in this study are comparable to the
levels found in a study demonstrating the efﬁcacy of DEGR
VIIa in preventing restenosis (13). This, together with the
concordant results of the other extrinsic pathway inhibitor,
TFPI, suggests that inadequate dosing is unlikely to be respon-
sible for the observed lack of efﬁcacy of DEGR VIIa.
We thank Mirella Ezben, PhD (Novo Nordisk, Copenhagen, Denmark) for
assistance in the manufacture and characterization of DEGR VIIa; Debra
Gilbertson, MS (ZymoGenetics Inc., Seattle, Washington) for assistance in
DEGR VIIa plasma measurements; and Gerald R. Galuppi, PhD (Monsanto
Co., St. Louis, MO) for determining tissue factor pathway inhibitor plasma
concentrations in this experiment.
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